These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37010614)

  • 1. Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia.
    Girbash EF; Sherif HE; Radwan AM; Abdeldayem HM
    Arch Gynecol Obstet; 2023 Sep; 308(3):947-952. PubMed ID: 37010614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
    Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
    Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.
    Nooh AM; Abdeldayem HM; Girbash EF; Arafa EM; Atwa K; Abdel-Raouf SM
    Reprod Sci; 2016 Apr; 23(4):448-54. PubMed ID: 26718306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia.
    Uysal G; Acmaz G; Madendag Y; Cagli F; Akkaya H; Madendag I; Karakilic EU
    Gynecol Obstet Invest; 2018; 83(2):151-155. PubMed ID: 28715800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
    Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
    Menopause; 1999; 6(4):299-306. PubMed ID: 10614676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women.
    Brynhildsen J; Hammar M
    Menopause; 2002; 9(2):137-44. PubMed ID: 11875333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women.
    Bouchard P; De Cicco-Nardone F; Spielmann D; Garcea N;
    Gynecol Endocrinol; 2005 Sep; 21(3):142-8. PubMed ID: 16353319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen.
    Rees MC; Kuhl H; Engelstein M; Mattila L; Mäenpää J; Mustonen M;
    Climacteric; 2004 Mar; 7(1):23-32. PubMed ID: 15259280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
    Ross AH; Boyd ME; Colgan TJ; Ferenczy A; Fugere P; Lorrain J
    Obstet Gynecol; 1993 Nov; 82(5):773-9. PubMed ID: 8414325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
    Mittermeier T; Farrant C; Wise MR
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial effects of transdermal estradiol/norethisterone acetate.
    Lindgren R; Risberg B; Hammar M; Berg G; Pryse-Davies J
    Maturitas; 1992 Aug; 15(1):71-8. PubMed ID: 1528133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study.
    Bruhat M; Rudolf K; Vaheri R; Kainulainen P; Timonen U; Viitanen A
    Maturitas; 2001 Dec; 40(3):259-71. PubMed ID: 11731187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
    Gräser T; Koytchev R; Müller A; Oettel M
    Climacteric; 2000 Jun; 3(2):109-18. PubMed ID: 11910651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group.
    Bjarnason K; Cerin A; Lindgren R; Weber T
    Maturitas; 1999 Aug; 32(3):161-70. PubMed ID: 10515673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.
    von Holst T; Lang E; Winkler U; Keil D
    Maturitas; 2002 Dec; 43(4):265-75. PubMed ID: 12468135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
    Sangkomkamhang US; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy.
    Stadberg E; Mattsson LA; Uvebrant M
    Maturitas; 1996 Feb; 23(1):31-9. PubMed ID: 8861084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.